Castle Biosciences, Inc. (CSTL) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CSTL Revenue Growth
Revenue Breakdown (FY 2025)
CSTL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CSTL Revenue Analysis (2017–2025)
As of May 8, 2026, Castle Biosciences, Inc. (CSTL) generated trailing twelve-month (TTM) revenue of $339.9 million, reflecting slight decline in growth of -4.9% year-over-year. The most recent quarter (Q1 2026) recorded $83.7 million in revenue, down 3.8% sequentially.
Looking at the longer-term picture, CSTL's 5-year compound annual growth rate (CAGR) stands at +40.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $344.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CSTL's business is primarily driven by Dermatologic (100%). With over half of revenue concentrated in Dermatologic, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NTRA (+35.9% YoY), EXAS (+17.7% YoY), and VCYT (+16.9% YoY), CSTL has underperformed the peer group in terms of revenue growth. Compare CSTL vs NTRA →
CSTL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CSTLCurrent | $340M | -4.9% | +40.6% | -12.4% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 FLGT | $323M | +13.8% | -5.2% | -28.2% |
CSTL Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $344.2M | +3.7% | $236.3M | 68.7% | $-42,810,000 | -12.4% |
| 2024 | $332.1M | +51.1% | $271.9M | 81.9% | $8.7M | 2.6% |
| 2023 | $219.8M | +60.4% | $174.8M | 79.5% | $-67,977,000 | -30.9% |
| 2022 | $137.0M | +45.7% | $105.0M | 76.6% | $-72,855,000 | -53.2% |
| 2021 | $94.1M | +50.2% | $78.3M | 83.2% | $-40,079,000 | -42.6% |
| 2020 | $62.6M | +20.8% | $53.0M | 84.5% | $-6,542,000 | -10.4% |
| 2019 | $51.9M | +127.6% | $44.6M | 85.9% | $7.3M | 14.1% |
| 2018 | $22.8M | +65.7% | $17.5M | 76.8% | $-3,835,643 | -16.8% |
| 2017 | $13.8M | - | $8.8M | 64.2% | $-10,899,676 | -79.2% |
See CSTL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSTL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSTL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCSTL — Frequently Asked Questions
Quick answers to the most common questions about buying CSTL stock.
Is CSTL's revenue growth accelerating or slowing?
CSTL revenue growth slowed to -4.9%, below the 5-year CAGR of +40.6%. TTM revenue is $340M. The deceleration marks a shift from historical growth rates.
What is CSTL's long-term revenue growth rate?
Castle Biosciences, Inc.'s 5-year revenue CAGR of +40.6% reflects the variable expansion pattern. Current YoY growth of -4.9% is near this long-term average.
How is CSTL's revenue distributed by segment?
CSTL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.